[go: up one dir, main page]

WO2025078645A1 - Utilisation cosmétique d'au moins l'urolithine b ou c sur une peau sensible - Google Patents

Utilisation cosmétique d'au moins l'urolithine b ou c sur une peau sensible Download PDF

Info

Publication number
WO2025078645A1
WO2025078645A1 PCT/EP2024/078764 EP2024078764W WO2025078645A1 WO 2025078645 A1 WO2025078645 A1 WO 2025078645A1 EP 2024078764 W EP2024078764 W EP 2024078764W WO 2025078645 A1 WO2025078645 A1 WO 2025078645A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
compound
formula
urolithin
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/078764
Other languages
English (en)
Inventor
Samira TAMOUTOUNOUR
Juliane ROBERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR2311030A external-priority patent/FR3153997A1/fr
Priority claimed from FR2311020A external-priority patent/FR3153996A1/fr
Application filed by LOreal SA filed Critical LOreal SA
Publication of WO2025078645A1 publication Critical patent/WO2025078645A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin

Definitions

  • the present invention relates to the cosmetic use of at least one compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates, for preventing and/or treating a skin manifestation on sensitive skin.
  • compound of formula (I) preferably urolithin B or urolithin C
  • salts and/or one of its isomers and/or one of its solvates such as hydrates
  • the skin is capable of responding to external physicochemical and mechanical stimuli, giving rise to warning sensations such as stinging and itching. These stimuli are of varied origin.
  • Sensitive skin is defined as non-pathological skin, which may display adverse skin manifestations.
  • undesirable skin manifestations may be expressed in two aspects, namely sensations of discomfort felt on the skin and/or onset of visible skin signs.
  • sensations of discomfort may typically consist of itching, heating, stinging and/or tautness sensations.
  • sensations of discomfort may typically consist of itching, heating, stinging and/or tautness sensations.
  • redness As a representation of visible skin signs, mention may in particular be made of redness.
  • This skin reactivity conventionally results in the manifestation of signs of discomfort in response to the subject coming into contact with a triggering element which may have various origins.
  • These skin reactions may occur in particular on areas subjected to certain daily or frequently repeated hygiene activities such as shaving, hair removal, cleaning with toiletry products or cleaning products, application of adhesives (dressings, patches, attachment of prosthetics) or in the case of activities associated with sports, occupations or simply lifestyle and the use of clothing, tools or equipment generating localized friction, and the intake of certain foods. They may also be amplified by temperature variations, wind and psychological stress.
  • dysesthetic sensations means more or less painful sensations perceived in a skin area such as stinging, tingling, itching, heating, discomfort, tautness, etc. These subjective signs exist most often in the absence of visible clinical signs such as redness or desquamation.
  • the reactivity of sensitive skin is not related to a process resulting in an inflammatory response.
  • compositions capable of preventing and/or treating these undesirable skin manifestations.
  • the aim of the present invention is specifically that of meeting this need.
  • the present invention thus relates to the cosmetic use of at least one compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates: wherein:
  • - R1 is -OH
  • - R2 and R3 are identical and are each either -H or -OH, for preventing and/or treating a skin manifestation on sensitive skin.
  • the compounds of formula (I) are natural urolithins.
  • the compound of formula (I) is chosen from urolithin B and urolithin C.
  • Urolithin B or 3-hydroxy-6H-benzo[c]chromen-6-one, is the compound having the following general formula (II):
  • Urolithin B like urolithin C, are a microbial metabolite produced by enzyme catabolism in commensal bacteria from the intestine from ellagic acid and low-bioavailability ellagitannins.
  • Ellagic acid and ellagitannins are obtained from edible plants such as berries, tropical fruits such as pomegranate and medicinal plants such as Camellia sinensis.
  • Urolithin C or 3,8,9-trihydroxy-6H-benzo[c]chromen-6-one, is the compound having the following general formula (III):
  • the compound of formula (I) is urolithin B.
  • salt of a compound of formula (I), preferably of urolithin B or urolithin C, according to the invention means a salt formed by an inorganic or organic base.
  • base salts examples include alkali metal hydroxides such as sodium, potassium and lithium; alkali earth-metal hydroxides such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia and organic amines such as non-substituted or hydroxy-substituted mono-, di- or tri-alkylamines; dicyclohexylamines; tributyl amines; pyridine; N-methyl-N-ethylamine; diethylamine; triethylamine; mono-, bis- or tris-(2-hydroxy-alkylamines) such as mono-, bis- or tris-(2- hydroxyethyl)amine, 2-hydroxy-tert-butylamine ortris-(hydroxymethyl)methylamine, N, N-di- alkyl-N-(hydroxyalkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(
  • the expression "skin manifestation" covers sensations of discomfort, in a subject in particular with sensitive skin, as well as temporary visible and unsightly skin signs capable of affecting said subject.
  • the skin manifestation is a sensation of discomfort.
  • the subject is a subject with sensitive skin, preferably a human subject.
  • skin means all the skin of the body, and preferably the skin of the face, scalp, neckline, neck, arms and forearms, or even more preferably, the skin of the face (in particular the forehead, nose, cheeks, chin), neckline and neck.
  • the sensations of discomfort may be itching, heating, stinging and/or tautness.
  • the skin manifestation on a sensitive skin according to the invention is expressed by the manifestation of one or more visible skin signs such as redness and desquamation.
  • the present invention relates to the cosmetic use of at least one compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates, as a soothing agent.
  • the term “soothing agent” means an agent capable of reducing a skin manifestation, preferably on a normal skin, in particular capable of reducing redness and/or a sensation of discomfort.
  • normal skin it is meant a non-pathological and non-sensitive skin.
  • the soothing agent is a skin-soothing agent, preferably a topical skin-soothing agent.
  • the aim of the invention is in particular that of preventing and/or reducing sensations of skin discomfort, such as for example stinging, tingling, itching, heating, discomfort and/or tautness, in particular in people with sensitive skins.
  • the compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates according to the invention is administered topically.
  • the invention relates to a cosmetic treatment process comprising topical application on a subject's sensitive skin of a cosmetic composition comprising at least one compound of formula (I), preferably urolithin B or urolithin C and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates.
  • a cosmetic composition comprising at least one compound of formula (I), preferably urolithin B or urolithin C and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates.
  • prevent means reducing the risk of manifestation of a phenomenon.
  • the term "treat” means compensate for a physiological dysfunction and more generally reduce, or suppress, an undesirable disorder, the manifestation of which is in particular a consequence of this dysfunction.
  • TRPV1 transient receptor potential vanilloid 1
  • SLIGRL protease
  • PAR2 receptor Protease- Activated Receptor-2
  • TRPV1 Gouin, O., et al., TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization. Protein Cell, 2017. 8(9): p. 644-661).
  • the activation of these channels results in the genesis of an intracellular calcium flux, the release of neuromediators and the activation of a signaling cascade causing the sensation of discomfort.
  • sensitive skins covers reactive skins and intolerant skins.
  • An intolerant skin is a skin which reacts at least with sensations of heating, tautness, tingling and/or redness, to various factors such as the application of cosmetic or dermatological products or soap. In general, these signs are associated with hyper- seborrheic skin.
  • a reactive skin is a skin which reacts by itching or stinging, to various factors such as the environment, emotions, foods, wind, friction, shaving, hard water with a high limescale concentration, temperature variations, humidity or wool.
  • this type of skin may be associated with dry skin or skin presenting with redness. Dry skin is essentially manifested by a sensation of tautness and/or tension. The skin is also rough to the touch and appears to be covered with flakes. When the skin is slightly dry, these flakes are plentiful and difficult to see with the naked eye. They are less and less numerous but increasingly visible with the naked eye when this disorder worsens.
  • the sensitive skins in question do not exhibit any inflammatory signs.
  • the compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates may be formulated in a composition at a rate of at least 0.00001% by weight, in particular at a rate of 0.0001 to 20% by weight and more particularly at a rate of 0.001 to 2% by weight with respect to the total weight of the composition.
  • compositions according to the invention may be presented in any dosage forms normally available for the selected mode of administration.
  • the substrate may be of various natures according to the type of composition in question.
  • the compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates according to the invention is administered topically, i.e. on the skin surface.
  • topical compositions mention may be made of aqueous, hydroalcoholic or oily solutions, dispersions such as lotion or serum, emulsions of liquid or semi-liquid consistency such as milk, suspensions or emulsions such as cream, aqueous or anhydrous gel, microemulsions, microcapsules, microparticles or ionic and/or non-ionic vesicular dispersions. These compositions are prepared using routine methods.
  • compositions may in particular constitute creams for cleansing, protection, treatment or care for the face, hands, feet, for the major anatomical folds or for the body (for example day creams, night creams, cleansing, foundation creams, sun creams), makeup products such as fluid foundations, makeup-removing milks, body milks for protection or care, after-sun milks, lotions, gels or foams for skin care, such as cleansing and disinfection lotions, sun lotions, artificial tanning lotions, bath compositions, deodorant compositions containing a bactericidal agent, aftershave gels or lotions, depilatory creams or compositions against insect bites.
  • creams for cleansing, protection, treatment or care for the face, hands, feet for the major anatomical folds or for the body
  • makeup products such as fluid foundations, makeup-removing milks, body milks for protection or care
  • after-sun milks lotions, gels or foams for skin care
  • cleansing and disinfection lotions sun lotions, artificial tanning lotions, bath
  • compositions according to the invention may also consist of solid preparations constituting soaps or cleansing bars.
  • compositions may also be used for the scalp in the form of solutions, creams, gels, emulsions, mousses, or alternatively in the form of aerosol compositions also containing a propellant under pressure.
  • compositions according to the invention may comprise one or more routine adjuvants in the cosmetic field, such as organic solvents, hydrophilic or lipophilic gelling agents, preservatives, fatty substances such as oils, emulsifiers, antioxidants, solvents, perfumes, fillers, sun filters, odor absorbers, dyestuffs and mixtures thereof.
  • routine adjuvants in the cosmetic field such as organic solvents, hydrophilic or lipophilic gelling agents, preservatives, fatty substances such as oils, emulsifiers, antioxidants, solvents, perfumes, fillers, sun filters, odor absorbers, dyestuffs and mixtures thereof.
  • routine adjuvants in the cosmetic field such as organic solvents, hydrophilic or lipophilic gelling agents, preservatives, fatty substances such as oils, emulsifiers, antioxidants, solvents, perfumes, fillers, sun filters, odor absorbers, dyestuffs and mixtures thereof.
  • fatty substances such as oils, emuls
  • adjuvants as well as their concentrations, must be such that they do not harm the advantageous properties of the compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates.
  • organic solvents suitable for use in the composition of the invention mention may be made of water-miscible organic solvents.
  • water-miscible solvent means a compound that is liquid at ambient temperature and water-miscible, having in particular a miscibility in water greater than 50% by weight at 25°C and atmospheric pressure.
  • the water-miscible organic solvents may be chosen from lower monoalcohols having 1 to 5 carbon atoms such as ethanol and isopropanol, glycols having 2 to 8 carbon atoms such as ethylene glycol, hexylene glycol, propylene glycol, 1,3-butylene glycol, pentylene glycol, dipropylene glycol, and glycerin.
  • oils suitable for use in the composition of the invention mention may be made for example of:
  • esters and ethers in particular of fatty acids, such as the oils of formulas R1COOR2 and R1OR2 wherein R1 represents the residue of a fatty acid including 8 to 29 carbon atoms, and R2 represents a hydrocarbon chain, branched or not, containing 3 to 30 carbon atoms;
  • hydrocarbon oil in the list of oils cited above denotes any oil comprising mostly carbon and hydrogen atoms, and optionally ester, ether, fluorinated, carboxylic acid and/or alcohol groups.
  • the other fatty substances that could be present in the oily phase are for example fatty acids including 8 to 30 carbon atoms; waxes; silicone resins; and silicone elastomers. These fatty substances may be selected in varied ways by those skilled in the art in order to prepare a composition having the desired properties, for example in terms of consistency or texture.
  • the composition used within the scope of the invention is anhydrous.
  • anhydrous means a composition comprising less than 5% by weight of water with respect to the total weight of the composition, preferably less than 3% by weight, even more preferably less than 1 % with respect to the total weight of the composition, or even totally free from water (0%).
  • the composition used within the scope of the invention is a water-in-oil (W/O) or oil-in-water (O/W) emulsion.
  • W/O water-in-oil
  • O/W oil-in-water
  • the proportion of the oily phase of the emulsion may range from 5 to 90% by weight, and preferably from 5 to 60% by weight relative to the total weight of the composition.
  • the emulsions generally contain at least one emulsifier selected from amphoteric, anionic, cationic or non-ionic emulsifiers, used alone or in a mixture, and optionally a coemulsifier.
  • the emulsifiers are suitably selected according to the emulsion to be obtained (W/O or O/W).
  • the emulsifier and the co-emulsifier are present, in the composition, in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight with respect to the total weight of the composition.
  • O/W emulsifiers in particular non-ionic emulsifiers such as esters of fatty acid and polyethylene glycol, esters of fatty acid and glycerin as well as W/O emulsifiers such as dimethicone copolyols, alkyl-dimethicone copolyols, cross-linked elastomer solid organopolysiloxane including at least one oxyalkylenated group.
  • hydrophilic gelling agents By way of hydrophilic gelling agents, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays; by way of lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
  • fillers which can be used in the composition of the invention, mention may be made, besides pigments, of silica powder; talc; starch; polyamide particles; polyethylene powders; acrylic copolymer-based microspheres; expanded powders such as hollow microspheres; silicone resin microbeads; and mixtures thereof. These fillers may be present in quantities ranging from 0.1 to 20% by weight and preferably from 1 to 10% by weight with respect to the total weight of the composition or the preparation according to the invention.
  • the invention also relates to a cosmetic treatment process comprising topical application on a subject's sensitive skin of a cosmetic composition comprising at least one compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates.
  • a cosmetic treatment process comprising topical application on a subject's sensitive skin of a cosmetic composition
  • a cosmetic composition comprising at least one compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates.
  • the cosmetic treatment process of the invention may be implemented in particular by administering the cosmetic and/or dermatological compositions as defined above, according to the usual technique of use of these compositions. For example: application of creams, gels, serums, lotions, makeup-removing milks or after-sun compositions on the skin or dry scalp, application of a hair lotion or shampoo to the wet scalp, regarding topical application.
  • the cosmetic treatment process according to the invention may thus be implemented by topical administration, for example daily, of one compound of formula (I), preferably urolithin B or urolithin C, and/or one of its salts and/or one of its isomers and/or one of its solvates such as hydrates.
  • one compound of formula (I) preferably urolithin B or urolithin C
  • one of its salts and/or one of its isomers and/or one of its solvates such as hydrates.
  • the process according to the invention may comprise single administration.
  • the administration is repeated for example 2 to 3 times daily for one or more days, and generally over a prolonged period of at least 4 weeks, or 4 to 15 weeks, with where applicable one or more break periods.
  • a soothing effect is obtained if intracellular calcium flux inhibition is observed.
  • the calcium channel receptors studied are those of the histamine pathway, i.e. H1R and H4R.
  • H1 receptor and H4 (H4R) receptors dopamine pathway
  • histamine receptors are currently described, including the H1 and H4 receptors expressed by keratinocytes. They consist of transmembrane receptors belonging to the GPCR family and coupled with a calcium channel, they are directly activated by endogenous histamine. In the keratinocyte, histamine binding on these specific receptors activates the PLC and PIP2 pathway and these mechanisms result in vivo in itching sensations which may sometimes be accompanied by stinging and/or redness. In the case of sensitive skin and with a view to soothing, the neutralization of this pathway could have the consequence of essentially reducing itching.
  • HCE Human Corneal Epithelial cells are inoculated in sterile black Advanced TC (Greiner) 96-well plates at the cellular density of 20,000 cells/well/0.2ml for testing 48h after inoculation, and 10,000 cells/well/0.2ml for testing 72h after inoculation.
  • the molecules tested are urolithin A from Sigma Aldrich (SML-1791), and urolithin B. a. Solubility of the molecules to be evaluated
  • the solubility of each molecule is preferably tested in HBSS buffer (Gibco-lnvitrogen) supplemented with 20mM of HEPES (Gibco-lnvitrogen) and adjusted to pH 7.4.
  • HBSS buffer Gibco-lnvitrogen
  • HEPES Gibco-lnvitrogen
  • DMSO Sigma-Aldrich
  • ethanol Prolabo
  • a molecule soluble in DMSO the final DMSO concentration administered to the keratinocytes is 2% whereas for a molecule soluble in ethanol, the final ethanol concentration must not exceed 1%.
  • Each molecule is tested in the agonist version of the test in order to ensure the non-activation of the receptors by the molecule before evaluating its soothing properties.
  • the maximum dose tested is determined according to the nonactivation of the receptors but also the solubility of the molecules and/or their cytotoxicity on the cells. 3 maximum concentrations are tested per molecule and are produced by successive dilutions.
  • the maximum dose tested on the HCE keratinocyte cells is 1 mg/ml.
  • the calcium concentration is measured using the 5pM fura-2AM Ester fluorescent probe (Molecular Probes).
  • the probe is previously solubilized in DMSO.
  • An equal volume of 10% Pluronic F-127 surfactant (Molecular Probes) is added for better solubilization of the probe.
  • the cells are washed twice in HBSS buffer then incubated for 30 minutes at 37°C in the presence of the previously prepared calcium probe. 2 washes in HBSS buffer are performed before subsequently treating the cells for 30 minutes at ambient temperature and protected from light with the solutions of molecule to be evaluated at the defined concentrations. d. Preparation of the reference agonist solution
  • the reference H1 R and H4R pathway agonist solution is prepared extemporaneously then deposited in a 96-well plate enabling automatic injection on the cells in order to perform real-time monitoring of the calcium influx.
  • the reference H1 R and H4R pathway agonist is histamine (Sigma-Aldrich), soluble in HBSS buffer, used at 4.5 mM. e. Real-time calcium influx monitoring
  • the fluorescence is measured on a FlexStation 3 microplate reader (Molecular Devices) at a double excitation wavelength: 340 nm (bound Ca 2+ ), 380nm (free Ca 2+ ) and at an emission length of 510 nm.
  • the measurements are made for 30 seconds - baseline - and for 3 minutes after the automatic injection by the Flexstation of the reference agonists (agonists or HBSS buffer or DMSO or ethanol, volume of 50pl/well). 7 controls are produced in parallel: HBSS control; DMSO and ethanol control if required and Activation Control.
  • Each condition is replicated on at least 2 independent tests with 6 wells per condition and per test.
  • the results are expressed as a ratio of the fluorescence intensity of 2 wavelengths (340nm/380nm) and processed as a % variation of the ratio on a kinetics of 10 to 300 seconds.
  • Urolithin B has a calcium flux inhibition percentages after H1 R and H4R that is approximately 90% at 47 pM, whereas urolithin A has an inhibition of merely 87% at 44 pM (Table 2).
  • Urolithin B has H1 R and H4R inhibition capabilities that are at least 10% greater than urolithin A. Therefore, urolithin B has strong potential for reducing itching in sensitive skin.
  • % Calcium flux variation ((fluorescence intensity at 340nm for x second(s) I fluorescence intensity at 380nm for x second(s)) - (fluorescence intensity at 340nm to I fluorescence intensity at 380nm t0)) I (fluorescence intensity at 340nm to I fluorescence intensity at 380nm tO).
  • % inhibition 100 - ((% Variation of calcium flux of compound "X" x 100) / % Variation of calcium flux of H1R and H4R receptor agonist, i.e. histamine) [Table 2]
  • Urolithin B has a superior inhibitory effect to urolithin A on H1 R and H4R, suggesting a greater antagonistic effect of urolithin B on H1 R and H4R than that observed with urolithin A.
  • Urolithin B has a soothing effect and could be used on the following skin conditions: stinging, tautness, discomfort, itching, redness and/or sensation of heating of the skin (including the scalp).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation cosmétique d'au moins un composé de formule (I) et/ou de l'un de ses sels et/ou de l'un de ses isomères et/ou de l'un de ses solvates tels que les hydrates, pour prévenir et/ou traiter une manifestation cutanée sur la peau sensible.
PCT/EP2024/078764 2023-10-13 2024-10-11 Utilisation cosmétique d'au moins l'urolithine b ou c sur une peau sensible Pending WO2025078645A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FRFR2311030 2023-10-13
FR2311030A FR3153997A1 (fr) 2023-10-13 2023-10-13 Utilisation cosmétique d'au moins l’urolithine B sur une peau sensible
FRFR2311020 2023-10-13
FR2311020A FR3153996A1 (fr) 2023-10-13 2023-10-13 Utilisation cosmétique d'au moins l’urolithine C sur une peau sensible

Publications (1)

Publication Number Publication Date
WO2025078645A1 true WO2025078645A1 (fr) 2025-04-17

Family

ID=93014946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/078764 Pending WO2025078645A1 (fr) 2023-10-13 2024-10-11 Utilisation cosmétique d'au moins l'urolithine b ou c sur une peau sensible

Country Status (1)

Country Link
WO (1) WO2025078645A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3028177A1 (fr) * 2014-11-06 2016-05-13 Oreal Utilisation de l'association d'acide ascorbique et d'acide ellagique en tant qu'agent apaisant
WO2020110089A1 (fr) * 2018-11-29 2020-06-04 Warszawski Uniwersytet Medyczny Urolithine a et composition la contenant pour utilisation externe dans des inflammations de diverses étiologies
JP2023107934A (ja) * 2012-06-27 2023-08-03 アマゼンティス エスアー ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
US20230293458A1 (en) * 2017-06-05 2023-09-21 Flagship Pioneering Innovations V, Inc. Multibiotic agents and methods of using the same
WO2023180214A1 (fr) * 2022-03-22 2023-09-28 Amazentis Sa Compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023107934A (ja) * 2012-06-27 2023-08-03 アマゼンティス エスアー ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
FR3028177A1 (fr) * 2014-11-06 2016-05-13 Oreal Utilisation de l'association d'acide ascorbique et d'acide ellagique en tant qu'agent apaisant
US20230293458A1 (en) * 2017-06-05 2023-09-21 Flagship Pioneering Innovations V, Inc. Multibiotic agents and methods of using the same
WO2020110089A1 (fr) * 2018-11-29 2020-06-04 Warszawski Uniwersytet Medyczny Urolithine a et composition la contenant pour utilisation externe dans des inflammations de diverses étiologies
WO2023180214A1 (fr) * 2022-03-22 2023-09-28 Amazentis Sa Compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERARDESCA E ET AL: "Sensitive skin: an overview", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 35, no. 1, 21 September 2012 (2012-09-21), pages 2 - 8, XP071470037, ISSN: 0142-5463, DOI: 10.1111/J.1468-2494.2012.00754.X *
GOUIN OLIVIER ET AL: "TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization", PROTEIN & CELL, SPRINGER ASIA, BEIJING, CN, vol. 8, no. 9, 31 March 2017 (2017-03-31), pages 644 - 661, XP036302077, ISSN: 1674-800X, [retrieved on 20170331], DOI: 10.1007/S13238-017-0395-5 *
GOUIN, O. ET AL.: "TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization", PROTEIN CELL, vol. 8, no. 9, 2017, pages 644 - 661, XP036302077, DOI: 10.1007/s13238-017-0395-5

Similar Documents

Publication Publication Date Title
CA2470201C (fr) Compositions et procede d'administration pour le traitement de rides, fins sillons et de l'hyperhidrose
AU2010267964B2 (en) L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin
JP6891211B2 (ja) 抗アレルギー化粧品組成物
JP2006131645A (ja) 少なくとも１つのカルシウムチャンネルの少なくとも１つのインヒビターのシワの処置における用途
HK1224198A1 (zh) 包含胆汁酸- 脂肪酸缀合物的抗老化组合物
ES2318866T3 (es) Utilizacion de un inhibidor de aminoacidos excitatorio en una composicion cosmetica o dermatologica para pieles sensibles y composicion obtenida.
KR20150028201A (ko) 흑효모 배양액을 포함하는 피부상태 개선용 화장료 조성물
DE69500576T2 (de) Verwendung eines Ethylendiaminderivats in einer kosmetischen und/oder dermatologischen Zusammensetzung und Zusammensetzung, die insbesondere ein Produkt mit reizender Nebenwirkung enthaelt
JP2015503577A (ja) クニフォフィア・ウバリア種子の抽出物、それを含有する化粧用又は皮膚用組成物、並びにそれらの使用
KR101503158B1 (ko) 피부 주름 개선 및 탄력 증진용 화장료 조성물
JP2012001519A (ja) 組成物
JP2003231626A (ja) Ａｔｐ産生促進剤
WO2025078645A1 (fr) Utilisation cosmétique d'au moins l'urolithine b ou c sur une peau sensible
KR20160133007A (ko) 피부 노화의 징후를 감소시키기 위한 추출물의 조합을 포함하는 국소 조성물
WO2025078619A1 (fr) Utilisation cosmétique de l'iso-urolithine a sur peau sensible
JP2005289873A (ja) シワ改善用皮膚外用剤
JP2003146886A (ja) フィラグリン合成促進剤、及び角質層保湿機能改善剤，角質層柔軟化剤，角質層遊離アミノ酸増加剤
KR101734801B1 (ko) 추출물들의 조합을 이용한 피부 노화 징후 감소 방법
FR3153997A1 (fr) Utilisation cosmétique d'au moins l’urolithine B sur une peau sensible
FR3153996A1 (fr) Utilisation cosmétique d'au moins l’urolithine C sur une peau sensible
WO2008028950A1 (fr) Utilisation du 1,6-bis[3-(3-carboxyméthylphényl)-4-(2-alpha-d-mannopyranosyl-oxy)-phényl]hexane pour la préparation de compositions cosmétiques
JP2001511782A (ja) 敏感肌のための化粧品または皮膚科用組成物における５ｈｔ▲下２▼及び５ｈｔ▲下１ｄ▼レセプターそれぞれに特異的なセロトニンアンタゴニストまたはアゴニストの使用
Somwanshi et al. Cosmetic Science
DE102007003582A1 (de) Verwendung einer kosmetischen Zusammensetzung zur kosmetischen Behandlung der Haut
Grosick et al. Efficacy as used, not as tested, is true measure of sunscreen performance 1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24786846

Country of ref document: EP

Kind code of ref document: A1